Recent Finacing
Recent Raise
DalCor Pharmaceuticals develops precision cardiovascular therapies, advancing dalcetrapib—a CETP inhibitor targeted to ADCY9 rs1967309 AA‑genotype patients—using a Roche companion diagnostic and planned Phase III trials.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at DalCor Pharmaceuticals.
